Dabalak Signs Over 2,407 Billion Rial Deal to Sell Cefixime Pharmaceutical Raw Material

Dabalak announced in a material disclosure filed with Codal on the afternoon of Wednesday, September 30, 2026 (8 Mehr 1405), that it had signed a contract worth 2,407,173 million rials (over 2,407 billion rials) to sell cefixime pharmaceutical raw material to Exir Pharmaceutical Company.

Under the disclosure, payment will be settled in stages in proportion to the goods delivered. The company estimated the contract's gross profit margin at about 30 percent. Both the signing date and the effective date of the contract are recorded as September 30, 2026.